Navigation Links
NxStage(R) Announces Extension of Medisystems Needle Supply and Distribution Agreement
Date:7/21/2009

LAWRENCE, Mass., July 21 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems subsidiary has extended for three years a supply and distribution agreement with Fenwal, Inc. of Lake Zurich, Ill. Medisystems provides needle sets and assemblies to Fenwal, a global medical technology company focused on improving blood collection, separation, safety and availability for patient care. Medisystems products involved in this agreement include the MasterGuard needle sets with FingerShield(TM) safety technology, the leading worldwide needle-stick prevention device.

"Medisystems is delighted to continue its relationship with Fenwal," said Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical. "This agreement provides further validation of our ability to continue to drive steady growth in end-user demand with Medisystems' innovative, high quality, value added product offerings."

MasterGuard Anti-Stick Needle Protector is the only guarded pheresis needle proven to reduce needlestick injuries, as compared to conventional, unguarded needles. Medisystems' patented FingerShield technology helps protect medical technicians' and caregivers' pressure-holding fingers during pheresis procedures. MasterGuard is also designed to allow for optimal visualization of the needle and does not interfere with site selection, cannulation technique or tapedown for patient safety and procedural efficacy during pheresis.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. Medisystems, a wholly owned subsidiary of NxStage, designs, manufactures, imports and distributes innovative medical devices, primarily for use in dialysis and related blood treatments (www.medisystems.com). For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NxStage(R) Announces Medisystems(R) Bloodline Distribution Agreement with Gambro
2. NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloittes 2008 Technology Fast 500
3. NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy
4. Emil Paganini, MD, Joins NxStage(R) as Critical Care Medical Advisor
5. NxStage(R) Medical to Report Fourth Quarter & Full Year 2007 Financial Results on Tuesday, February 12th
6. The Neutraceutical Company Announces Powerful New Feel-Good Product
7. Domain Registration Corp. Announces Name Change to BioPharm Asia, Inc.
8. PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009
9. Owensboro Medical Health System Announces Results of Its Modified Dutch Auction Tender Offer
10. PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009
11. Domain Registration Corp. Announces Name Change to BioPharm Asia, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... Featured ... provide a unique keynote address at the 2016 Learning Summit , June ... five community college students. Their stories—of complicated family issues, financial difficulties, and other ...
(Date:5/6/2016)... ... May 06, 2016 , ... Bluvault ( Bluvault Inc. ... offering for global clients of Coupa ( Coupa Software ) and other Cloud ... is a key component in the suite of innovative implementation services offered by ...
(Date:5/6/2016)... ... May 06, 2016 , ... Logically, spring weather, with ... when the weather is too cold, dry or hot, water on the eye surface ... absorb moisture from the surrounding air. There’s only one problem, according to radio show ...
(Date:5/6/2016)... ... May 06, 2016 , ... From the Speaker Podium to the Exhibit Floor ... its insights on managing Customers Engagement at SpeechTek 2016 Event, taking place May 23-25 ... deliver a Presentation on “5 Customer Engagement Strategies to improve Customer Satisfaction ...
(Date:5/6/2016)... ... May 06, 2016 , ... Expert ... . , Since launching in September, 2014 Sleepopolis has resided at Sleepopolis-mattress-reviews.com ... now include pillows, sheets, mattress toppers, bed frames, and more. , Founder and ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , May 5, 2016 ... of the  "Europe Systemic Lupus Erythematosus Market ... to their offering.       (Logo: ... latest research Europe Systemic Lupus Erythematosus Market ... comprehensive insights into Systemic Lupus Erythematosus pipeline ...
(Date:5/4/2016)... 2016  It,s time for an upgrade. There are many medical recorders on the ... LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a ... class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... Yissum Research Development Company of the ... had signed an exclusive world-wide licensing and research agreement ... degradation and immunomodulatory drugs for cancer and immune dysfunction, ... first-in-class therapy for hematologic and solid malignancies. Financial terms ... novel technology was developed by Yinon Ben-Neriah , ...
Breaking Medicine Technology: